Novartis AG Other Long-Term Assets 2010-2024 | NVS

Novartis AG other long-term assets from 2010 to 2024. Other long-term assets can be defined as field containing the sum of all non-current assets that cannot be standardized into another field as well as those that are aggregated by the company because materially, they are too small to list separately.
  • Novartis AG other long-term assets for the quarter ending September 30, 2024 were $1.389B, a 25.25% increase year-over-year.
  • Novartis AG other long-term assets for 2023 were $1.199B, a 8.02% increase from 2022.
  • Novartis AG other long-term assets for 2022 were $1.11B, a 49.77% decline from 2021.
  • Novartis AG other long-term assets for 2021 were $2.21B, a 147.76% increase from 2020.
Novartis AG Annual Other Long-Term Assets
(Millions of US $)
2023 $1,199
2022 $1,110
2021 $2,210
2020 $892
2019 $3,256
2018 $895
2017 $818
2016 $698
2015 $601
2014 $554
2013 $525
2012 $505
2011 $456
2010 $405
2009 $328
Novartis AG Quarterly Other Long-Term Assets
(Millions of US $)
2024-09-30 $1,389
2024-06-30 $1,655
2024-03-31 $1,209
2023-12-31 $1,199
2023-09-30 $1,109
2023-06-30 $1,208
2023-03-31 $1,211
2022-12-31 $1,110
2022-09-30 $3,194
2022-06-30 $3,885
2022-03-31 $3,861
2021-12-31 $2,210
2021-09-30 $2,127
2021-06-30 $2,212
2021-03-31 $1,586
2020-12-31 $892
2020-09-30 $850
2020-06-30 $866
2020-03-31 $3,206
2019-12-31 $3,256
2019-09-30 $3,467
2019-06-30 $4,137
2019-03-31 $626
2018-12-31 $895
2018-09-30 $1,178
2018-06-30 $843
2018-03-31 $818
2017-12-31 $818
2017-09-30 $28,692
2017-06-30
2017-03-31 $27,722
2016-12-31 $698
2016-09-30 $27,723
2016-06-30 $26,904
2016-03-31 $27,351
2015-12-31 $601
2015-09-30 $27,072
2015-06-30 $27,569
2015-03-31 $26,473
2014-12-31 $554
2014-09-30 $18,740
2014-06-30 $19,392
2014-03-31 $18,865
2013-12-31 $525
2013-09-30 $18,537
2013-06-30 $17,412
2013-03-31 $17,146
2012-12-31 $505
2012-09-30 $16,965
2012-06-30 $16,220
2012-03-31 $15,905
2011-12-31 $456
2011-09-30 $16,257
2011-06-30 $17,251
2011-03-31 $16,445
2010-12-31 $405
2010-09-30 $15,832
2010-06-30 $23,553
2010-03-31 $24,847
2009-12-31 $328
2009-09-30 $24,024
2009-06-30 $23,017
2009-03-31 $22,995
Sector Industry Market Cap Revenue
Medical Large Cap Pharmaceutical $217.584B $45.440B
Novartis has one of the strongest and broadest portfolio of oncology drugs and generics. It continues to build depth in 5 core therapeutic areas Cardio-Renal, Immunology, Neuroscience, Oncology and Hematology, strength in technology platforms - Targeted Protein Degradation, Cell Therapy, Gene Therapy, Radioligand Therapy, and xRNA. Novartis efforts to strengthen its wide and deep oncology portfolio by developing breakthrough treatments. Cosentyx, Entresto, Kesimpta, Zolgensma, Kisqali and Leqvio. In March 2015, Novartis acquired certain oncology products and pipeline compounds from Glaxo. In exchange, it sold its non-influenza Vaccines business to Glaxo. Also, the company has spun off the Alcon business into a separate company. In January 2015, Novartis divested its Animal Health division to Lilly. In July 2015, the company divested its influenza vaccines business to CSL Limited. Novartis has also acquired The Medicines Company, adding Leqvio, to its portfolio. Novartis sold its investment in Roche.
Stock Name Country Market Cap PE Ratio
Eli Lilly (LLY) United States $789.394B 81.76
Novo Nordisk (NVO) Denmark $481.063B 34.69
Johnson & Johnson (JNJ) United States $374.313B 15.18
AbbVie (ABBV) United States $352.544B 18.56
Merck (MRK) United States $260.350B 17.30
AstraZeneca (AZN) United Kingdom $199.957B 17.81
Pfizer (PFE) United States $151.422B 10.36
Sanofi (SNY) $130.241B 11.80
Innoviva (INVA) United States $1.263B 10.51